Patent · US Active

Cancer therapy

US9603912B2 · kind B2 · utility

0Cited by
2References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 23, 2010
Grant dateMar 28, 2017
Priority date
Expiry dateSep 7, 2033

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

An agent that stimulates antiviral immunity may be used, for the treatment of cancer. A product comprising an immunostimulant and a vector comprising a transgene that promotes death of neoplastic cells, may also be used for simultaneous, sequential or separate administration in the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.